Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 9/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648250 | 0.89 | IDO1 (0.39) | KDM4EDPP4IDO1 | |
| SCHEMBL8750546 | 0.82 | L3MBTL1 (0.44) | KDM4EIDO1 | |
| SCHEMBL18892799 | 0.80 | NPSR1 (0.37) | SMN1; SMN2DPP4IDO1 | |
| SCHEMBL8846751 | 0.78 | DPP4 (0.35) | KDM4EDPP4IDO1TAAR1 | |
| SCHEMBL29618473 | 0.78 | CYP4F2 (0.49) | KDM4EIDO1 | |
| SCHEMBL7689047 | 0.78 | ALDH1A1 (0.47) | SMN1; SMN2IDO1 | |
| SCHEMBL3149558 | 0.78 | TSHR (0.35) | DPP4IDO1 | |
| SCHEMBL19535134 | 0.78 | IDO1 (0.57) | KDM4EDPP4IDO1TAAR1 | |
| SCHEMBL18892755 | 0.78 | CYP4F2 (0.49) | KDM4EIDO1 | |
| SCHEMBL21796063 | 0.77 | TACR1 (0.38) | KDM4EDPP4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| US-4992588-A | Preparation of o-acylaminomethylbenzyl halides | BASF AKTIENGESELLSCHAFT (DE) | 1991-02-12 | — | — | US | disclosed |
| EP-0087676-B1 | PROCESS FOR THE PREPARATION OF O-ACYLAMINOMETHYLBENZYL HALOGENIDES | BASF Aktiengesellschaft (DE) | 1987-12-16 | — | — | EP | disclosed |
| EP-0087676-A1 | Process for the preparation of o-acylaminomethylbenzyl halogenides | BASF Aktiengesellschaft (DE) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | KDM4E 571/4885SMN1; SMN2 3377/4885PNMT 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.